Session Information
-
WCLC 2017
18th World Conference on Lung Cancer
Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan
Download PDF of the Conference Program: Click Here.
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
Financial Disclosure Summary (PDF): Click Here.Presentation Date(s):- Oct 15 - 18, 2017
- Total Presentations: 2295
October 14 Sat
Oct 14 Sunday
October 15 Sun
Oct 15 Monday
October 16 Mon
Oct 16 Tuesday
October 17 Tue
Oct 17 Wednesday
October 18 Wed
Oct 18
-
+
P1.07 - Immunology and Immunotherapy
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Immunology and Immunotherapy
-
+
P1.07-010 - Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab
09:30 - 09:30 | Presenter: Junko Tanizaki | Author(s): K. Haratani, Hidetoshi Hayashi, Y. Chiba, Kimio Yonesaka, K. Kudo, H. Kaneda, Y. Hasegawa, K. Tanaka, M. Takeda, Kazuhiko Nakagawa
- Abstract
Loading...
-
+
OA 05 - Next Generation TKI
- 15:45 - 17:30
- 10/16/2017
- Location: Room 301 + 302
- Type: Oral
- Track: Advanced NSCLC
- Moderators:James Chih-Hsin Yang, Fiona Blackhall
-
+
OA 05.01 - First-Line Dacomitinib versus Gefitinib in Advanced Non-Small-Cell Lung Cancer with EGFR Mutation Subgroups
15:45 - 15:55 | Presenter: Yi-Long Wu | Author(s): Ying Cheng, X. Zhou, K.H. Lee, Kazuhiko Nakagawa, Seiji Niho, F. Tsuji, Rafael Rosell, J. Corral, M.R. Migliorino, A. Pluzanski, R. Linke, E.I. Sbar, T. Wang, H. Zhang, Tony SK Mok
- Abstract
Loading... -
+
OA 05.03 - Clinical Activity of ASP8273 in Asian Non-Small Cell Lung Cancer Patients with EGFR Activating and T790M Mutations
16:05 - 16:15 | Presenter: Keunchil Park | Author(s): K. Azuma, C. Tsai, Takashi Seto, H. Nokihara, James Chih-Hsin Yang, Sang-We Kim, H. Murakami, Makoto Nishio, K. Kiura, A. Inoue, K. Takeda, Jin-Hyoung Kang, Hidetoshi Hayashi, T. Nakagawa, Y. Kaneko, R. Akazawa, M. Shimazaki, S. Morita, M. Fukuoka, Kazuhiko Nakagawa
- Abstract
Loading... -
+
OA 05.08 - Final Result of Phase I/II Study (AF-001JP) of Alectinib, a Selective CNS-Active ALK Inhibitor, in ALK+ NSCLC Patients (Pts)
17:00 - 17:10 | Presenter: Makoto Nishio | Author(s): K. Kiura, Takashi Seto, Kazuhiko Nakagawa, M. Maemondo, A. Inoue, T. Hida, H. Yoshioka, M. Harada, Yuichiro Ohe, N. Nogami, H. Murakami, K. Takeuchi, S. Inamura, H. Kuriki, T. Shimada, T. Tamura
- Abstract
Loading...
-
+
P2.03 - Chemotherapy/Targeted Therapy
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
-
+
P2.03-008 - Phase I/II Study of Intermitted Erlotinib in Combination with Docetaxel in Patients with Recurrent NSCLC with Wild-Type EGFR: WJOG 4708L
09:30 - 09:30 | Presenter: Tatsuo Kimura | Author(s): Tomoya Kawaguchi, S. Kudoh, Y. Chiba, H. Yoshioka, K. Watanabe, T. Kijima, Y. Kogure, T. Oguri, Naruo Yoshimura, T. Niwa, T. Kasai, Hidetoshi Hayashi, A. Ono, H. Tanaka, S. Yano, S. Nakamura, Nobuyuki Yamamoto, Yoichi Nakanishi, Kazuhiko Nakagawa
- Abstract
Loading... -
+
P2.03-045 - Updated Results of Phase II, Liquid Biopsy Study in EGFR Mutated NSCLC Patients Treated with Afatinib (WJOG 8114LTR)
09:30 - 09:30 | Presenter: Hidetoshi Hayashi | Author(s): H. Akamatsu, Y. Koh, S. Morita, Daichi Fujimoto, Isamu Okamoto, A. Bessho, K. Azuma, Kazuhiko Nakagawa, Nobuyuki Yamamoto
- Abstract
Loading... -
+
P2.03-058a - T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive NSCLC
09:30 - 09:30 | Presenter: Takeshi Yoshida | Author(s): S. Watanabe, H. Kawakami, N. Takegawa, Junko Tanizaki, Hidetoshi Hayashi, M. Takeda, Kimio Yonesaka, J. Tsurutani, Kazuhiko Nakagawa
- Abstract
No abstract available for this presentation
-
+
P2.07 - Immunology and Immunotherapy
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Immunology and Immunotherapy
-
+
P2.07-021 - A Checkpoint Molecule B7-H3 as a Novel Immune Therapy Target for Non-Small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Presenter: Kimio Yonesaka | Author(s): K. Kudoh, S. Takamura, H. Sakai, R. Kato, K. Haratani, T. Takahama, K. Tanaka, Hidetoshi Hayashi, H. Kaneda, M. Takeda, O. Maenishi, M. Yamato, M. Miyazawa, Kazuto Nishio, Kazuhiko Nakagawa
- Abstract
Loading...
-
+
P2.15 - SCLC/Neuroendocrine Tumors
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: SCLC/Neuroendocrine Tumors
-
+
P2.15-004 - Underrepresentation of Elderly Patients with ED-SCLC as Clinical Trial Candidates (JCOG1201/TORG1528)
09:30 - 09:30 | Presenter: Yuki Misumi | Author(s): Tsuneo Shimokawa, Hiroaki Okamoto, Shinji Atagi, H. Tanaka, Koichi Goto, Kazuhiko Nakagawa, T. Hida, Nobuyuki Yamamoto, Y. Hosomi, Terufumi Kato, Isamu Okamoto, Yuichiro Ohe
- Abstract
Loading...
-
+
P3.01 - Advanced NSCLC
- 09:30 - 16:00
- 10/18/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
-
+
P3.01-012 - Symptom Impact of First-Line Dacomitinib versus Gefitinib in EGFR-Positive NSCLC: Results from a Randomized Phase 3 Study
09:30 - 09:30 | Presenter: Rickard Sandin | Author(s): M.R. Migliorino, Tony SK Mok, Yi-Long Wu, X. Zhou, K.H. Lee, Kazuhiko Nakagawa, Seiji Niho, F. Tsuji, R. Linke, Rafael Rosell, J. Corral, A. Pluzanski, E.I. Sbar, A. Reisman, T. Wang, J.L. White, Ying Cheng
- Abstract
Loading... -
+
P3.01-071 - Randomized Phase 1b/3 Study of Erlotinib + Ramucirumab in Untreated EGFR Mutation-Positive Stage IV NSCLC: Phase 1b Outcomes
09:30 - 09:30 | Presenter: Kazuhiko Nakagawa | Author(s): Edward Brian Garon, Luis Paz-Ares, S. Ponce, J. Corral Jaime, O. Juan Vidal, Ernest Nadal, K. Kiura, Keunchil Park, R.C. Widau, E. Alexandris, S. He, P. Lee, Martin Reck
- Abstract
Loading... -
+
P3.01-072 - Dacomitinib Versus Gefitinib for First-Line Treatment of Advanced EGFR+ NSCLC in Japanese Patients (ARCHER 1050)
09:30 - 09:30 | Presenter: Kazuhiko Nakagawa | Author(s): F. Ohyanagi, Terufumi Kato, T. Takahashi, H. Kaneda, N. Nogami, Seiji Niho, N. Yamamoto, Y. Fujita, H. Zhang, E.I. Sbar, T. Wang, R. Linke, F. Tsuji, Tony SK Mok
- Abstract
Loading...
-
+
MA 19 - Mesothelioma: Bench to Bedside
- 11:00 - 12:30
- 10/18/2017
- Location: Room 315
- Type: Mini Oral
- Track: Mesothelioma
- Moderators:Dean A Fennell, Hedy Lee Kindler
-
+
MA 19.01 - A Phase II Study of Nivolumab: A Multicenter, Open-Label, Single Arm Study in Malignant Pleural Mesothelioma (MERIT)
11:00 - 11:05 | Presenter: Yasushi Goto | Author(s): Morihito Okada, T. Kijima, K. Aoe, Terufumi Kato, N. Fujimoto, Kazuhiko Nakagawa, Y. Takeda, T. Hida, K. Kanai, F. Imamura, S. Oizumi, T. Takahashi, M. Takenoyama, H. Tanaka, Yuichiro Ohe
- Abstract
Loading...
-
+
PC 03 - 3-1 What is the Optimal Sequence of ALK-TKI for ALK-Positive Lung Cancer? (Alectinib First or Crizotinib First)
- 11:00 - 11:40
- 10/18/2017
- Location: Room 303 + 304
- Type: Pros & Cons
- Track: Chemotherapy/Targeted Therapy
- Moderators:Rafal Dziadziuszko, Y.O. Tan
-
+
PC 03.02 - Alectinib First
11:20 - 11:40 | Presenter: Kazuhiko Nakagawa
- Abstract
No abstract available for this presentation